DTDo Minh Thai

Do Minh Thai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Do Minh Thai has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Colon cancer risk and different HRT formulations: a case-control study

    by Jürgen C Dinger, Lothar Aj Heinemann, Sabine Möhner, Do Minh Thai, Anita Assmann

    Background: Most studies have found no increased risk of colon cancer associated with hormone replacement therapy (HRT), or even a decreased risk. But information about the effects of different HRT preparations is lacking. Methods: A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers. Up to 5 controls were matched to each case of colon cancer. Conditional logistic regression analysis was applied to estimate crude and adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Stratified analyses were performed to get an impression of the risk associated with different estrogens and progestins. Results: A total of 354 cases of colon cancer were compared with 1422 matched controls. The adjusted overall risk estimate for colon cancer (ColC) associated with ever-use of HRT was 0.97 (0.71 – 1.32). No clinically relevant trends for ColC risk were observed with increasing duration of HRT use, or increasing time since first or last HRT use in aggregate. Whereas the overall risk estimates were stable, the numbers in many of the sub-analyses of HRT preparation groups (estrogens and progestins) were too small for conclusions. Nevertheless, if the ColC risk estimates are taken at face value, most seemed to be reduced compared with never-use of HRT, but did not vary much across HRT formulation subgroups. In particular, no substantial difference in ColC risk was observed between HRT-containing conjugated equine estrogens (CEE) or medroxyprogesterone acetate (MPA) and other formulations more common in Europe. Conclusion: Ever-use of HRT was not associated with an increased risk of colon cancer. In contrary, most risk estimates pointed non-significantly toward a lower ColC risk in HRT ever user. They did not vary markedly among different HRT formulations (estrogens, progestins). However, the small numbers and the overlapping nature of the subgroups suggest cautious interpretation.


  • Open Access

    Breast cancer risk associated with different HRT formulations: a register-based case-control study

    by Juergen C Dinger, Lothar Aj Heinemann, Sabine Möhner, Do Minh Thai, Anita Assmann

    Background: Previous epidemiological studies have inconsistently shown a modestly increased breast cancer risk associated with hormone replacement therapy (HRT). Limited information is available about different formulations – particularly concerning different progestins. Methods: A case-control study was performed within Germany in collaboration with regional cancer registries and tumor centers. Up to 5 controls were matched breast cancer cases. Conditional logistic regression analysis was applied to estimate crude and adjusted odds ratios (OR) and 95% confidence intervals (95% CI). Stratified analyses were performed to compare the risk of different estrogens, progestins, and combinations. Results: A total of 3593 cases of breast cancer were identified and compared with 9098 controls. The adjusted overall risk estimate for breast cancer (BC) associated with current or past use of HRT was 1.2 (1.1–1.3), and almost identical for lag times from 6 months to 6 years prior to diagnosis. No significant trend of increasing BC risk was found with increasing duration of HRT use, or time since first or last use in aggregate. Many established BC risk factors significantly modified the effect of HRT on BC risk, particularly first-degree family history of BC, higher age, lower education, higher body mass index (BMI), and never having used oral contraceptives (OCs) during lifetime. Whereas the overall risk estimates were stable, the numbers in many of the sub-analyses of HRT formulation groups (estrogens, progestins, and combinations) were too small for strong conclusions. Nevertheless, the BC risk seems not to vary much across HRT formulation subgroups. In particular, no substantial difference in BC risk was observed between HRT containing conjugated equine estrogens (CEE) or medroxyprogesterone acetate (MPA) and other formulations more common in Europe. Conclusion: The BC risk of HRT use is rather small. Low risk estimates for BC and a high potential for residual confounding and bias in this observational study do not permit causal conclusions. Apparently, there is not much variation of the BC risk across HRT formulations (estrogens, progestins). However, the small numbers and the overlapping nature of some of the subgroups suggest cautious interpretation.


  • The Risk of Gynecological Cancers Associated With Different HRT Formulations. A Nested Case-Control Study in the German Cohort Study on Women's Health - Gynecological Tumors and HRT Use

    by J. Dinger, L. Heinemann, Do Minh Thai, S. Möhner, A. Assmann, C. Thiel

    Hintergrund: Epidemiologische Studien haben bisher sowohl leicht erhöhte als auch leicht erniedrigte Risiken für Brust-, Corpus-uteri- und Ovarialkrebs bei HRT-Nutzung gezeigt. Wenige Informationen liegen über die unterschiedlichen HRT-Präparate vor; dies gilt insbesondere hinsichtlich der verwendeten Gestagene. Methodik: Es wurde eine Fallkontrollstudie innerhalb der Deutschen Kohortenstudie zur Frauengesundheit eingebettet (nested case-control study) und bezüglich gynäkologischer Malignome bei HRT-Nutzung bzw. Niemalsnutzung analysiert. Die Analysen erfolgten mittels logistischer Regression, wobei jeweils die Rohwerte und adjustierte Werte für die Odds Ratios (OR) und die 95 %-Konfidenzintervalle (95 % CI) berechnet wurden. Stratifizierte Analysen wurden durchgeführt, um das Risiko verschiedener Estrogene und Gestagene in verschiedener Zusammensetzung und Anwendungsregimes vergleichen zu können. Ergebnisse: 427 Fälle von Brust-, 69 von Corpus-uteri- und 35 von Ovarialkrebs wurden in der Kohortenstudie identifiziert und mit 1614, 263 und 135 Kontrollen für Brust-, Corpus-uteri-, und Ovarialkrebs verglichen. Das adjustierte Gesamtrisiko für Brust-, Corpus-uteri- und Ovarialkrebs wurde mit 1.0 (0.8 - 1.3), 0.6 (0.2 - 1.5) und 0.2 (0.04 - 0.8) bestimmt. Der Ausschluss von unterschiedlich langen HRT-Expositionszeiten unmittelbar vor der Krebsdiagnose führt zu keinen wesentlichen Veränderungen der Risikoschätzungen. Auch die Dauer der HRT-Nutzung und die Zeit seit erster bzw. seit letzter HRT-Nutzung zeigten keinen eindeutigen Einfluss auf das Krebsrisiko. Zwischen den unterschiedlichen HRT-Zusammensetzungen gab es keine offensichtlichen Risikounterschiede für gynäkologische Malignome. Die Zahlen waren jedoch für die Subgruppen von Corpus-uteri- und Ovarialkrebs zu klein, um endgültige Schlussfolgerungen abzuleiten. Schlussfolgerungen: Die Risikoschätzungen für Frauen, die jemals ein HRT-Präparat eingenommen haben, liegen zwischen 1.0 und 1.1. Eine HRT-Nutzung scheint auch nicht mit einem erhöhten Risiko für Corpus-uteri- und Ovarialkrebs assoziiert zu sein. Darüber hinaus konnte kein eindeutiger Zusammenhang zwischen Krebsrisiko und Behandlungsdauer, Zeit seit erster oder Zeit seit letzter HRT-Nutzung festgestellt werden. Verschiedene HRT-Präparate (Zusammensetzung und Anwendungsregime) scheinen nicht mit unterschiedlichen Krebsrisiken assoziiert zu sein. Background: Previous epidemiological studies have inconsistently shown an increased or decreased risk of cancer of the breast, ovary, and uterine corpus in users of HRT. Limited information is available about different formulations - particularly concerning different progestins. Methods: A nested case-control study within the German Cohort Study on Women's Health was analyzed concerning the risk of gynecological malignancies in HRT users as opposed to never users. Logistic regression analysis was applied to estimate crude and adjusted odds ratios (OR) and 95 % confidence intervals (95 % CI). Stratified analyses were performed to compare the risk of different estrogens and progestins in different formulations. Results: 427 cases of breast cancer, 69 of uterine corpus cancer, and 35 of ovarian cancer were identified in the cohort and compared with 1614, 263, and 135 controls for breast, uterine corpus, and ovarian cancer, respectively. The adjusted overall risk estimates for breast, uterine corpus, and ovarian cancer were 1.0 (0.8 - 1.3), 0.6 (0.2 - 1.5), and 0.2 (0.04 - 0.8) for breast, uterine corpus, and ovarian cancer, respectively. No clear trend of increasing risk with increasing lag-time between exposure and tumor diagnosis was observed. No clear time trends for the risk of gynecological cancer were observed with respect to duration of use, time since first HRT use, or time since last use. No obvious differences in the risk of gynecological cancer were found for the different HRT formulations; the numbers in the subgroups for uterine corpus and ovarian cancer, however, were too small to draw final conclusions. Conclusion: Ever-use of hormone replacement therapy is associated with risk estimates very close to unity (1.0 - 1.1). HRT use appears not to be associated with an increased risk of uterine corpus or ovarian cancer. In addition, no significant cancer risk trend was observed for duration of use or for time since first or last use. Different HRT formulations (composition and regimen) appear not to be associated with different cancer risks. These results need confirmation in a larger, sufficiently powered, case-control study.


  • Open Access

    Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: A community-based cohort study

    by Michael Spannagl, Lothar Aj Heinemann, Thai DoMinh, Anita Assmann, Wolfgang Schramm, Rolf Schürmann

    Background: Little information is available from community-based long-term VTE cohort studies to compare the absolute thrombosis risk of established clinical and genetic risk factors. Materials and methods: The occurrence of venous thromboembolism (VTE) was observed during a 10-year observation period in the BAvarian ThromboEmbolic Risk (BATER) study, a cohort study of 4337 women (age 18–55 years). We collected data on demographics, reproductive life, lifestyle, conditions/diseases, and particularly potential risk factors for VTE with a self-administered questionnaire. The objective was to present incidence rates of VTE and to show relative risk estimated associated with different clinical and genetic risk factors. Results: 34 new, by diagnostic means confirmed VTE events occurred during the observation time of 32,656 women-years (WY). The overall incidence of VTE was 10.4 per 104 WY. The incidence rates varied markedly among different risk cohorts. The highest incidence was observed in women with previous history of VTE, followed by family history of VTE. None of the measured "genetically-related risk markers" (antithrombin, protein C, FVL, prothrombin mutation, or MTHFR) showed a significant VTE risk. Conclusion: Most of the discussed VTE risk factors showed no significant association with the occurrence of new VTEs due to smallness of numbers. Only first-degree family history of VTE and own history of a previous VTE event depicted a significant association with future VTE. Clinical information seems to be more important to determine future VTE risk than genetically related laboratory tests.


  • Open Access

    VTE Risk assessment – a prognostic Model: BATER Cohort Study of young women

    by Lothar Aj Heinemann, Thai DoMinh, Anita Assmann, Wolfgang Schramm, Rolf Schürmann, Jan Hilpert, Michael Spannagl

    Background: Community-based cohort studies are not available that evaluated the predictive power of both clinical and genetic risk factors for venous thromboembolism (VTE). There is, however, clinical need to forecast the likelihood of future occurrence of VTE, at least qualitatively, to support decisions about intensity of diagnostic or preventive measures. Materials and methods: A 10-year observation period of the Bavarian Thromboembolic Risk (BATER) study, a cohort study of 4337 women (18–55 years), was used to develop a predictive model of VTE based on clinical and genetic variables at baseline (1993). The objective was to prepare a probabilistic scheme that discriminates women with virtually no VTE risk from those at higher levels of absolute VTE risk in the foreseeable future. A multivariate analysis determined which variables at baseline were the best predictors of a future VTE event, provided a ranking according to the predictive power, and permitted to design a simple graphic scheme to assess the individual VTE risk using five predictor variables. Results: Thirty-four new confirmed VTEs occurred during the observation period of over 32,000 women-years (WYs). A model was developed mainly based on clinical information (personal history of previous VTE and family history of VTE, age, BMI) and one composite genetic risk markers (combining Factor V Leiden and Prothrombin G20210A Mutation). Four levels of increasing VTE risk were arbitrarily defined to map the prevalence in the study population: No/low risk of VTE (61.3%), moderate risk (21.1%), high risk (6.0%), very high risk of future VTE (0.9%). In 10.6% of the population the risk assessment was not possible due to lacking VTE cases. The average incidence rates for VTE in these four levels were: 4.1, 12.3, 47.2, and 170.5 per 104 WYs for no, moderate, high, and very high risk, respectively. Conclusion: Our prognostic tool – containing clinical information (and if available also genetic data) – seems to be worthwhile testing in medical practice in order to confirm or refute the positive findings of this study. Our cohort study will be continued to include more VTE cases and to increase predictive value of the model.


  • Top Cited Papers
    Open Access

    The Menopause Rating Scale (MRS) scale: A methodological review

    by Klaas Heinemann, Alexander Ruebig, Peter Potthoff, Hermann Pg Schneider, Frank Strelow, Lothar Aj Heinemann, Do Minh Thai

    Background: This paper compiles data from different sources to get a first comprehensive picture of psychometric and other methodological characteristics of the Menopause Rating Scale (MRS) scale. The scale was designed and standardized as a self-administered scale to (a) to assess symptoms/complaints of aging women under different conditions, (b) to evaluate the severity of symptoms over time, and (c) to measure changes pre- and postmenopause replacement therapy. The scale became widespread used (available in 10 languages). Method: A large multinational survey (9 countries in 4 continents) from 2001/ 2002 is the basis for in depth analyses on reliability and validity of the MRS. Additional small convenience samples were used to get first impressions about test-retest reliability. The data were centrally analyzed. Data from a postmarketing HRT study were used to estimate discriminative validity. Results: Reliability measures (consistency and test-retest stability) were found to be good across countries, although the sample size for test-retest reliability was small. Validity: The internal structure of the MRS across countries was astonishingly similar to conclude that the scale really measures the same phenomenon in symptomatic women. The sub-scores and total score correlations were high (0.7–0.9) but lower among the sub-scales (0.5–0.7). This however suggests that the subscales are not fully independent. Norm values from different populations were presented showing that a direct comparison between Europe and North America is possible, but caution recommended with comparisons of data from Latin America and Indonesia. But this will not affect intra-individual comparisons within clinical trials. The comparison with the Kupperman Index showed sufficiently good correlations, illustrating an adept criterion-oriented validity. The same is true for the comparison with the generic quality-of-life scale SF-36 where also a sufficiently close association has been shown. Conclusion: The currently available methodological evidence points towards a high quality of the MRS scale to measure and to compare HRQoL of aging women in different regions and over time, it suggests a high reliability and high validity as far as the process of construct validation could be completed yet.


  • Open Access

    The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study

    by Lothar Aj Heinemann, Thai DoMinh, Frank Strelow, Silvia Gerbsch, Jörg Schnitker, Hermann Pg Schneider

    The Menopause Rating Scale is a health-related Quality of Life scale developed in the early 1990s and step-by-step validated since then. No methodologically detailed work on the utility of the scale to assess health-related changes after treatment was published before.


  • Open Access

    The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics

    by Isolde Daig, Lothar Aj Heinemann, Sehyun Kim, Somboon Leungwattanakij, Xavier Badia, Eric Myon, Claudia Moore, Farid Saad, Peter Potthoff, Do Minh Thai

    The current paper reviews data from different sources to get a closer impression on the psychometric and other methodological characteristics of the Aging Males' Symptoms (AMS) scale gathered recently. The scale was designed and standardized as self-administered scale to (a) to assess symptoms of aging (independent from those which are disease-related) between groups of males under different conditions, (b) to evaluate the severity of symptoms over time, and (c) to measure changes pre- and post androgen replacement therapy. The scale is in widespread use (14 languages).